BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 16, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vectibix panitumumab: Phase III data

Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
Product: Vectibix panitumumab
Business: Cancer
Molecular target: Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1)
Description: Human mAb against epidermal growth factor (EGF) receptor 1 (HER1; ErbB1)...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >